These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28613123)

  • 1. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
    [No Abstract]   [Full Text] [Related]  

  • 2. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib as treatment for patients with advanced hepatocellular cancer.
    Thillai K; Srikandarajah K; Ross P
    Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib for treatment of hepatocellular carcinoma.
    Sherman M
    Hepatology; 2018 Mar; 67(3):1162-1165. PubMed ID: 29059458
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
    Tovoli F; Lorenzo S; Barbera MA; Garajova I; Frega G; Palloni A; Pantaleo MA; Biasco G; Brandi G
    Future Oncol; 2017 Sep; 13(21):1893-1905. PubMed ID: 28693355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Parikh ND; Singal AG; Hutton DW
    Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.
    Gyawali B; Prasad V
    Nat Rev Clin Oncol; 2017 Nov; 14(11):653-654. PubMed ID: 28719584
    [No Abstract]   [Full Text] [Related]  

  • 11. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 12. Regorafenib Approved for Liver Cancer.
    Cancer Discov; 2017 Jul; 7(7):660. PubMed ID: 28522682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
    Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
    Naruto K; Kawaoka T; Amioka K; Ogawa Y; Chihiro K; Yoshikawa Y; Ando Y; Suehiro Y; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Murakami E; Nakahara T; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Takaki S; Mori N; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Kohno H; Kohno H; Moriya T; Naeshiro N; Azakami T; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):491-498. PubMed ID: 34000725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Regorafenib in patients with advanced hepatocellular carcinoma;current status and future perspective].
    Ogasawara S; Ooka Y; Kato N
    Nihon Shokakibyo Gakkai Zasshi; 2019; 116(1):28-35. PubMed ID: 30626851
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study.
    Sun P; Zhang Y; Tian S; Cui K; Zhong J; Zhang C; Wang D; Zhang B; Shi X; Li Z
    J Cancer Res Ther; 2024 Aug; 20(4):1344-1349. PubMed ID: 39206997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune oncology in hepatocellular carcinoma-hype and hope.
    Wörns MA; Galle PR
    Lancet; 2017 Jun; 389(10088):2448-2449. PubMed ID: 28434649
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.
    Yoshioka N; Kuzuya T; Ito T; Ishizu Y; Honda T; Ishikawa T; Ishigami M; Fujishiro M
    Intern Med; 2019 Oct; 58(19):2803-2808. PubMed ID: 31243207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND).
    Bozzarelli S; Rimassa L; Giordano L; Sala S; Tronconi MC; Pressiani T; Smiroldo V; Prete MG; Spaggiari P; Personeni N; Santoro A
    Future Oncol; 2019 Dec; 15(35):4009-4017. PubMed ID: 31746632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.